Clinical trial of folinic acid to reduce vincristine neurotoxicity

• Published in: Cancer chemotherapy and pharmacology 1986-01, Vol.17 (3), p.281-284
• Main Authors: JACKSON, D. V, MCMAHAN, R. A, POPE, E. K, CASE, L. D, COOPER, M. R, KAPLON, M. K, RICHARDS, F. II, STUART, J. J, WHITE, D. R, ZEKAN, P. J
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological and medical sciences; Breast Neoplasms - drug therapy; Drug Evaluation; Drug toxicity and drugs side effects treatment; Female; Humans; Leucovorin - administration & dosage; Medical sciences; Middle Aged; Nervous System Diseases - chemically induced; Nervous System Diseases - prevention & control; Pharmacology. Drug treatments; Toxicity: nervous system and muscle; Vincristine - administration & dosage; Vincristine - adverse effects; Vincristine - antagonists & inhibitors
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/BF00256700

In a murine model system, folinic acid demonstrated host-protective properties during administration of repetitive and lethal doses of vincristine (VCR). Subsequently, folinic acid was evaluated in patients receiving VCR during an adjuvant chemotherapy program for stage II carcinoma of the breast. The toxicities, cumulative VCR dosage, and percentage of ideal dosage observed in 18 patients receiving folinic acid have been compared with those observed in 70 patients who previously received VCR without folinic acid in the same chemotherapy program. All patients ideally were intended to receive VCR 1.0 mg/m2 weekly for 6 weeks, with dose modification for neurotoxicity. Treatment patients received folinic acid 800 mg PO daily in three divided doses during the 6-week course. The degree of neurotoxic manifestations of VCR was similar in the treatment and comparison patients. Absent to mild neurotoxicity was observed in approximately 70% of patients in both groups; moderate or greater neurotoxicity occurred in about 30% of patients in both groups. Full dosage (6.0 mg/m2) was attained in 7 (39%) treatment patients and 17 (24%) comparison patients (P = 0.21). The mean percentage of the ideal dosage of VCR was 73.7 +/- 28.7 in patients receiving folinic acid and 76.1 +/- 20.5 in those given only VCR (P = 0.69). Hematologic toxicities were similar in both groups, but nausea occurred more frequently in the folinic acid group. Folinic acid in this dose and schedule afforded no protection from the neurotoxic side effects of VCR.